Regencell Bioscience Shares Surge Over 16% Despite No Approved Products

Stock News

Mar 18

Regencell Bioscience Limited (RGC.US) saw its stock price jump more than 16% on Wednesday, reaching $26.70. The company is an early-stage biotechnology firm focused on the research, development, and commercialization of Traditional Chinese Medicine-based treatments for neurocognitive disorders and degenerative diseases, particularly ADHD and Autism Spectrum Disorder (ASD). In May of last year, market rumors suggested that Regencell had received FDA clinical trial approval for its next-generation neuromodulation chip and would collaborate with the top-tier medical institution Mayo Clinic on Parkinson's disease treatment research. The rumors also indicated that this neuromodulation chip technology represents a cutting-edge direction in the brain-computer interface field, with the company planning to use it to target a global market of approximately 10 million Parkinson's patients. Since its founding in 2014, Regencell Bioscience currently has no approved products, nothing available for sale, and has not generated any product revenue. The company previously stated that it does not expect to earn any revenue until its standardized TCM formulation products for ADHD and autism patients are commercialized in Hong Kong.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1180966273"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180966273\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180966273?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 22:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180966273","market":"hk","top_or_hot":-1,"title":"Regencell Bioscience Shares Surge Over 16% Despite No Approved Products","media":"Stock News","content":"<p>Regencell Bioscience Limited (RGC.US) saw its stock price jump more than 16% on Wednesday, reaching $26.70. The company is an early-stage biotechnology firm focused on the research, development, and commercialization of Traditional Chinese Medicine-based treatments for neurocognitive disorders and degenerative diseases, particularly ADHD and Autism Spectrum Disorder (ASD). In May of last year, market rumors suggested that Regencell had received FDA clinical trial approval for its next-generation neuromodulation chip and would collaborate with the top-tier medical institution Mayo Clinic on Parkinson's disease treatment research. The rumors also indicated that this neuromodulation chip technology represents a cutting-edge direction in the brain-computer interface field, with the company planning to use it to target a global market of approximately 10 million Parkinson's patients. Since its founding in 2014, Regencell Bioscience currently has no approved products, nothing available for sale, and has not generated any product revenue. The company previously stated that it does not expect to earn any revenue until its standardized TCM formulation products for ADHD and autism patients are commercialized in Hong Kong.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regencell Bioscience Shares Surge Over 16% Despite No Approved Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegencell Bioscience Shares Surge Over 16% Despite No Approved Products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-18 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Regencell Bioscience Limited (RGC.US) saw its stock price jump more than 16% on Wednesday, reaching $26.70. The company is an early-stage biotechnology firm focused on the research, development, and commercialization of Traditional Chinese Medicine-based treatments for neurocognitive disorders and degenerative diseases, particularly ADHD and Autism Spectrum Disorder (ASD). In May of last year, market rumors suggested that Regencell had received FDA clinical trial approval for its next-generation neuromodulation chip and would collaborate with the top-tier medical institution Mayo Clinic on Parkinson's disease treatment research. The rumors also indicated that this neuromodulation chip technology represents a cutting-edge direction in the brain-computer interface field, with the company planning to use it to target a global market of approximately 10 million Parkinson's patients. Since its founding in 2014, Regencell Bioscience currently has no approved products, nothing available for sale, and has not generated any product revenue. The company previously stated that it does not expect to earn any revenue until its standardized TCM formulation products for ADHD and autism patients are commercialized in Hong Kong.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1180966273","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180966273","pubTimestamp":1773845897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Regencell Bioscience Limited (RGC.US) saw its stock price jump more than 16% on Wednesday, reaching $26.70. The company is an early-stage biotechnology firm focused on the research, development, and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4539":"次新股","RGC":"脑再生科技"},"translate_title":"尽管没有获得批准的产品，Regencell Bioscience股价仍飙升超过16%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGC":1},"content_text":"Regencell Bioscience Limited (RGC.US) saw its stock price jump more than 16% on Wednesday, reaching $26.70. The company is an early-stage biotechnology firm focused on the research, development, and commercialization of Traditional Chinese Medicine-based treatments for neurocognitive disorders and degenerative diseases, particularly ADHD and Autism Spectrum Disorder (ASD). In May of last year, market rumors suggested that Regencell had received FDA clinical trial approval for its next-generation neuromodulation chip and would collaborate with the top-tier medical institution Mayo Clinic on Parkinson's disease treatment research. The rumors also indicated that this neuromodulation chip technology represents a cutting-edge direction in the brain-computer interface field, with the company planning to use it to target a global market of approximately 10 million Parkinson's patients. Since its founding in 2014, Regencell Bioscience currently has no approved products, nothing available for sale, and has not generated any product revenue. The company previously stated that it does not expect to earn any revenue until its standardized TCM formulation products for ADHD and autism patients are commercialized in Hong Kong.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}